Video: Blazing a short path to an accelerated approval in oncology

Cancer drug R&D has attracted billions of dollars in new investments as biopharma companies rush to stake out leading positions in hot new fields of research. With the FDA assisting with a raft of breakthrough drug designations and accelerated approvals in oncology, investigators have completely re-engineered timelines and development strategies for experimental therapies.

At the 2015 BIO conference in Philadelphia, FierceBiotech Editor-in-Chief John Carroll moderates a discussion on the future of cancer R&D, featuring leaders from AstraZeneca, Juno Therapeutics, Merck, Johnson & Johnson and GlaxoSmithKline.